TetraLogic Pharmaceuticals Corporation and its wholly-owned subsidiary TetraLogic Research and Development Corporation announced that they have completed the sale to Medivir AB of their SMAC mimetic program, including their clinical stage asset birinapant, and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the sale) for a purchase price of $12 million payable in cash at closing plus milestone payments of up to $153 million based on the development and commercialization of TetraLogic's product candidates by Medivir. In connection with the completion of the sale, Mr. J. Kevin Buchi, Dr. Mary Ann Gray, Mr. Michael Kishbauch, Mr. Paul Schmitt and Dr. Andrew Pecora each resigned as a member of the Board of Directors of the company, effective December 30, 2016.  The resignation was not a result of any disagreement with the company on any matter relating to the Company's operations, policies or practices.  Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as Chief Executive Officer of the company, Mr. Richard Sherman resigned as Senior Vice President, Secretary and General Counsel of the company, Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as Chief Operating Officer of the company.